|apersy|

Value | Commercial | Access

company news

Celebrating the first birthday of Apersy Consulting! 

It is not only a new year ahead but also the 1st birthday of Apersy. Twelve months during which I have been working with biotech and medtech companies, other consultancies and partners delivering strategic market access and reimbursement projects. 

I started with the vision to create independent market access services that can support health tech companies through the challenges of precision medicine, complex treatment regimens and care approaches that blur the boundaries between device, pharmaceuticals and digital. 

In this first year, the mix of projects across biotech, digital diagnostics and connected devices reassured me that this expertise and broad view on healthcare systems and reimbursement landscapes is needed. 

It’s time to celebrate Apersy’s achievements:

5 projects delivered!

From innovative RNA therapies, over AI diagnostics to orthopaedic technologies. Work has been at the cutting edge of innovative healthcare. 

Apersy was present at 5 conferences! 

Including a poster presentation! Market access, medtech, microbiome – again, the bigger picture of integrated care counted!

Many many…

…shorter advisory interventions, amazing conversations, introductions and pitches with health tech entrepreneurs, and the creation of great partnerships and collaborations with expert consultancies globally.

Three therapeutic areas stood out for me:

Oncology, women’s health, innovative medical aids

Networks of entrepreneurs

Apersy became a member of the competitive cluster Atlanpôle Biotherapies, Nantes, France. And I am personally a mentor for EIT Health Coaching and Mentoring Network.

What I am most proud of:

At the end of year 1, Apersy has mapped digital medical device reimbursement and digital health policies across 12 international markets.

Looking ahead to 2024: There are big changes happening in the EU market access environment in the next years: EU HTAR and changes to the EU pharmaceutical legislations are the big topics. I  am looking forward to leveraging my pan-European knowledge of HTA to support clients with new services to understand the EU HTA and considering its context in market access and pricing strategy.

Have a great start to 2024!

Other recent posts: